# ELARA (NCT03568461)

> Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

No report yet. It can be ordered.

- Drugs tested: tisagenlecleucel
- Indication: relapsed or refractory follicular lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03568461
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Follicular Lymphoma
- Interventions: tisagenlecleucel
- Enrollment: 98
- Primary outcome: Complete Response Rate (CRR) Per Independent Review Committee (IRC) Assessment

## Indexed commentary on ELARA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 32
- YouTube: 16
- Podcasts: 11
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=elara-nct03568461

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03568461", "email": "<work email>"}; the inbox owner confirms by the emailed link.